Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistCurexa – East, LLC, a compounding pharmacy in New Jersey, produced adulterated drug products in violation of federal law during an FDA inspection conducted August-September 2022. FDA investigators documented serious deficiencies including non-microbial contamination in production areas and inadequate cleaning of utensils, components, and containers when manufacturing hazardous drugs, which created risk of cross-contamination and rendered products potentially injurious to health. The facility's practices failed to meet current good manufacturing practice (CGMP) standards required under Section 503A of the Federal Food, Drug, and Cosmetic Act, despite the company's October 2022 response to the inspection findings.